What is the recommended management for immune checkpoint inhibitor (ICI)–induced inflammatory arthritis?

Management of ICI-Induced Inflammatory Arthritis

For ICI-induced inflammatory arthritis, manage based on severity grade: continue ICI with NSAIDs for grade 1; hold ICI and use prednisone 10-20 mg/day for grade 2; and hold ICI with prednisone 0.5-1 mg/kg for grade 3-4, escalating to DMARDs (methotrexate or TNF inhibitors) if no improvement within 2-4 weeks. 1

Grade-Based Treatment Algorithm

Grade 1 (Mild Pain with Inflammatory Symptoms)

Continue ICI therapy 2, 1

• Start NSAIDs: naproxen 500 mg BID or meloxicam 7.5-15 mg daily for 4-6 weeks 2
• If NSAIDs fail, add prednisone 10-20 mg daily for 2-4 weeks 2
• Consider intra-articular corticosteroid injection only if ≤2 joints affected and oral therapy ineffective 2
• If no improvement in 2-4 weeks, escalate to grade 2 management 2

Grade 2 (Moderate Pain Limiting Instrumental ADLs)

Hold ICI temporarily - resume when symptoms controlled on prednisone ≤10 mg/day 1

• Start prednisone 10-20 mg/day 1
• Refer to rheumatology to confirm inflammatory arthritis and assess for early bone damage 2, 1
• If improvement: taper over 4-6 weeks 1
• If no improvement after 4 weeks: treat as grade 3 1
• If unable to reduce prednisone below 10 mg/day after 6-8 weeks: add DMARD 1
• Consider intra-articular steroid injections for large joints 1

The 2021 ASCO guideline 1 shortened the timeframe for DMARD consideration from 3 months to 6-8 weeks compared to earlier recommendations, reflecting evolving understanding that earlier steroid-sparing therapy may be beneficial.

Grade 3-4 (Severe Pain, Irreversible Joint Damage, Limiting Self-Care ADLs)

Hold ICI - may resume only in consultation with rheumatology if recovery to grade 1 1

• Start prednisone 0.5-1 mg/kg daily 1
• Mandatory rheumatology referral 1
• If no improvement after 2 weeks or worsening: add DMARD 1

DMARD Options:

• Synthetic DMARDs: methotrexate (15-25 mg weekly with daily folic acid), leflunomide, hydroxychloroquine, sulfasalazine (alone or in combination) 2, 1, 3
• Biologic DMARDs: TNF inhibitors or IL-6 antagonists 1

Critical caveat: IL-6 inhibitors can cause intestinal perforation (though extremely rare) and should NOT be used in patients with concomitant immune-related colitis 1

Essential Pre-Treatment Screening

Before initiating DMARDs, mandatory screening includes: 2, 1

• Hepatitis B and C testing
• Latent/active tuberculosis testing (before anti-TNF therapy)
• Annual repeat screening if biologic treatment continues ≥1 year 1

Diagnostic Workup by Grade

All Grades

• Complete rheumatologic examination of all peripheral joints for tenderness, swelling, range of motion; spine examination 1
• Autoimmune panel: ANA, RF, anti-CCP, inflammatory markers (ESR, CRP) 1
• Consider HLA B27 if symptoms suggest reactive arthritis or affect spine 1
• Plain X-rays to exclude metastases and evaluate for erosions 1

Grade 2 and Higher

• Ultrasound or MRI if persistent arthritis unresponsive to treatment or suspicion of metastases/septic arthritis 1
• Consider arthrocentesis if septic or crystal-induced arthritis suspected 1

Monitoring Requirements

Serial rheumatologic examinations every 4-6 weeks after treatment initiation, including inflammatory markers 2, 1

Critical Clinical Pearls

Early recognition is critical to avoid erosive joint damage 1. Unlike other immune-related adverse events, ICI-induced inflammatory arthritis often requires prolonged treatment, making early initiation of steroid-sparing agents more important than with other irAEs 1.

Oligoarthritis (≤2 joints) can be treated early with intra-articular steroids - consider early rheumatology referral for this approach 1

The EULAR guideline 3 recommends targeting prednisone ≤10 mg/day as maintenance therapy based on preclinical and retrospective data suggesting higher doses may impact tumor outcomes, though this target is higher than for classical rheumatic diseases.

Methotrexate appears safe with long-term use alongside ICIs, with case series showing no safety issues over median follow-up >1 year 3. However, sulfasalazine may have higher hypersensitivity reaction rates in ICI-induced inflammatory arthritis, warranting caution 3.

Avoid abatacept due to theoretical risk of antagonizing antitumor ICI responses (though may consider in life-threatening situations) 3

ICI Continuation Decisions

The decision to hold or continue ICI should balance: 3

• Severity of arthritis
• Extent of required immunosuppression
• Tumor response and duration
• Future oncology treatment plan
• Shared decision-making with patient

Notably, several studies demonstrate ongoing clinical cancer benefit even after ICI discontinuation for immune-related adverse events 3.